Related Experiment Video
Updated: Mar 15, 2026
Assessment of Plasma Coagulation on Liver Tissue in a Large Animal Model In Vivo
Published on: August 4, 2018
Treatment of Coagulopathy Related to Hepatic Insufficiency
1Department of Pharmacy, Oregon Health & Science University, Portland, OR.
Insights
Management of hepatic coagulopathy requires careful consideration of bleeding and clotting risks. Standard tests may not fully reflect dynamic hemostatic changes in liver disease patients.
Area of Science:
- Hepatology
- Hematology
- Critical Care Medicine
Background:
- Hepatic insufficiency significantly alters hemostasis, leading to coagulopathy.
- Coagulopathy in liver disease presents complex challenges in managing bleeding and thrombosis.
Purpose of the Study:
- To review the medical management of coagulopathy in hepatic insufficiency.
- To focus on prevention and management of bleeding episodes.
- To address treatment and prevention of thromboembolic complications.
Main Methods:
- Comprehensive electronic search of PubMed using terms like 'hepatic coagulopathy' and 'liver failure'.
- Inclusion of original articles, reviews, guidelines, and consensus statements.
- Detailed review and summarization of peer-reviewed scientific data.
Main Results:
- Evaluation of hemostasis tests, prohemostatic agents, and transfusion strategies.
- Analysis of prophylactic anticoagulation and treatment of thromboembolic events.
- Evidence synthesis on managing hemostatic and thrombotic risks in liver insufficiency.
Conclusions:
- Hemostasis in hepatic insufficiency is dynamic and not fully captured by routine tests.
- Prohemostatic agents should be used judiciously, balancing bleeding vs. thrombotic risks.
- Restrictive transfusion strategies and individualized thromboembolic prophylaxis are crucial.
Objectives:
To provide a concise review of the medical management of coagulopathy related to hepatic insufficiency. This review will focus on prevention and management of bleeding episodes in patients with hepatic insufficiency. The treatment and prevention of thromboembolic complications will also be addressed.
Data Sources:
Electronic search of PubMed database using relevant search terms, including hepatic coagulopathy, hemorrhage, liver diseases, blood coagulation disorders, blood transfusion, disseminated intravascular coagulation, and liver failure. Subsequent searches were done on specific issues.
Study Selection:
Articles considered include original articles, review articles, guidelines, consensus statements, and conference proceedings.
Data Extraction:
A detailed review of scientific, peer-reviewed data was performed. Relevant publications were included and summarized.
Data Synthesis:
Available evidence is used to describe and summarize currently available tests of hemostasis, utilization of prohemostatic agents, transfusion strategies, use of prophylactic anticoagulation and treatment of thromboembolic events in patients with hepatic insufficiency.
Conclusions:
Dynamic changes to hemostasis occur in patients with hepatic insufficiency. Routine laboratory tests of hemostasis are unable to reflect these changes and should not be used exclusively to evaluate coagulopathy. Newer testing methods are available to provide data on the entire spectrum of clotting but are not validated in acute bleeding. Prohemostatic agents utilized to prevent bleeding should only be considered when the risk of bleeding outweighs the risk of thrombotic complications. Restrictive transfusion strategies may avoid exacerbation of acute bleeding. Prophylaxis against and treatment of thromboembolic events are necessary and should consider patient specific factors.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:29Venous Thrombosis III: Interprofessional Care
01:28Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
01:30Venous Thrombosis IV: Nursing Management
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...